The global cancer diagnostics market size was USD 143.62 billion in 2023, estimated at USD 156.25 billion in 2024 and is anticipated to reach around USD 354.66 billion by 2034, expanding at a CAGR of 8.54% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cancer Diagnostics Market, by Product Type, 2024-2034
8.1.1. Consumables (Antibodies, Kits & Reagents, Probes, Other Consumables)
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Instruments (Pathology-based Instruments, Slide Staining Systems, Tissue Processing Systems, Cell Processors, Others)
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Imaging Instruments (CT Systems, Ultrasound Systems, MRI Systems, Mammography Systems, Nuclear Imaging Systems)
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Biopsy Instruments
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Cancer Diagnostics Market, by Technology, 2024-2034
9.1.1. IVD Testing (PCR, ISH, IHC, NGS, Microarrays, Flow Cytometry, Immunoassays)
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Imaging (MRI, CT, PET, Mammography, Ultrasound)
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Biopsy Technique
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. Cancer Diagnostics Market, by Application, 2024-2034
10.1.1. Breast Cancer
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Colorectal Cancer
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Cervical Cancer
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Lung Cancer
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Prostate Cancer
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. Skin Cancer
10.1.6.1. Market Revenue and Forecast (2021-2034)
10.1.7. Blood Cancer
10.1.7.1. Market Revenue and Forecast (2021-2034)
10.1.8. Kidney Cancer
10.1.8.1. Market Revenue and Forecast (2021-2034)
10.1.9. Liver Cancer
10.1.9.1. Market Revenue and Forecast (2021-2034)
10.1.10. Pancreatic Cancer
10.1.10.1. Market Revenue and Forecast (2021-2034)
10.1.11. Ovarian Cancer
10.1.11.1. Market Revenue and Forecast (2021-2034)
10.1.12. Others
10.1.12.1. Market Revenue and Forecast (2021-2034)
11.1. Cancer Diagnostics Market, by End Use, 2024-2034
11.1.1. Hospitals and Clinics
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Diagnostic Laboratories
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Diagnostic Imaging Centers
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Research Institutes
11.1.4.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.2. Market Revenue and Forecast, by Technology (2021-2034)
12.1.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.4. Market Revenue and Forecast, by End Use (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.5.4. Market Revenue and Forecast, by End Use (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.6.4. Market Revenue and Forecast, by End Use (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.4. Market Revenue and Forecast, by End Use (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.5.4. Market Revenue and Forecast, by End Use (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.6.4. Market Revenue and Forecast, by End Use (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.7.4. Market Revenue and Forecast, by End Use (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.8.4. Market Revenue and Forecast, by End Use (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.4. Market Revenue and Forecast, by End Use (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.5.4. Market Revenue and Forecast, by End Use (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.6.4. Market Revenue and Forecast, by End Use (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.7.4. Market Revenue and Forecast, by End Use (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.8.4. Market Revenue and Forecast, by End Use (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.4. Market Revenue and Forecast, by End Use (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.5.4. Market Revenue and Forecast, by End Use (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.6.4. Market Revenue and Forecast, by End Use (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.7.4. Market Revenue and Forecast, by End Use (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.8.4. Market Revenue and Forecast, by End Use (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.4. Market Revenue and Forecast, by End Use (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.5.4. Market Revenue and Forecast, by End Use (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.6.4. Market Revenue and Forecast, by End Use (2021-2034)
13.1. Agilent Technologies, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Thermo Fisher Scientific, Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Illumina, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Becton, Dickinson and Company
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GE Healthcare
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. QIAGEN N.V.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Abbott Laboratories, Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Roche Diagnostics
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Siemens Healthcare
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Philips Healthcare
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. R. Bard, Inc.
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample